Bioporto A/S
CSE:BIOPOR
Bioporto A/S
Free Cash Flow
Bioporto A/S
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bioporto A/S
CSE:BIOPOR
|
Free Cash Flow
-kr68.7m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-17%
|
|
|
Genmab A/S
CSE:GMAB
|
Free Cash Flow
kr7.5B
|
CAGR 3-Years
56%
|
CAGR 5-Years
44%
|
CAGR 10-Years
63%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Free Cash Flow
-kr944m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-35%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Free Cash Flow
-€307.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-32%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Free Cash Flow
kr279m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Saniona AB
STO:SANION
|
Free Cash Flow
-kr72.4m
|
CAGR 3-Years
39%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
Bioporto A/S
Glance View
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
See Also
What is Bioporto A/S's Free Cash Flow?
Free Cash Flow
-68.7m
DKK
Based on the financial report for Sep 30, 2024, Bioporto A/S's Free Cash Flow amounts to -68.7m DKK.
What is Bioporto A/S's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-17%
Over the last year, the Free Cash Flow growth was 1%. The average annual Free Cash Flow growth rates for Bioporto A/S have been -5% over the past three years , -5% over the past five years , and -17% over the past ten years .
You don't have any saved screeners yet